Home/Filings/4/0001209191-20-040311
4//SEC Filing

FENTON DENNIS M 4

Accession 0001209191-20-040311

CIK 0001269021other

Filed

Jul 1, 8:00 PM ET

Accepted

Jul 2, 4:26 PM ET

Size

12.1 KB

Accession

0001209191-20-040311

Insider Transaction Report

Form 4
Period: 2020-07-02
Transactions
  • Disposition to Issuer

    Common Stock

    2020-07-02$18.00/sh13,194$237,4920 total
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2020-07-02$0.06/sh11,377$6830 total
    Exercise: $11.94Exp: 2030-06-11Common Stock (11,377 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2020-07-0244,9910 total
    Common Stock (44,991 underlying)
  • Disposition to Issuer

    Restricted Stock Units

    2020-07-02$18.00/sh7,281$131,0580 total
Footnotes (4)
  • [F1]Pursuant to the Agreement and Plan of Merger, dated as of May 5, 2020, by and among Portola Pharmaceuticals, Inc. (the "Issuer"), Alexion Pharmaceuticals, Inc. ("Alexion") and Odyssey Merger Sub Inc. ("Merger Sub") (the "Merger Agreement"), on July 2, 2020, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a direct, wholly owned subsidiary of Alexion (the "Merger"). At the effective time of the Merger (the "Effective Time"), these shares were canceled in exchange for $18.00 per share in cash, without interest and subject to any applicable withholding taxes.
  • [F2]At the Effective Time, each restricted stock unit ("RSU") was accelerated and canceled as of immediately prior to, and contingent upon, the Effective Time, in exchange for the right to receive a cash amount equal to the product of (i) the number of shares deliverable under such RSU multiplied by (ii) $18.00.
  • [F3]At the Effective Time, each of these unvested and outstanding options was accelerated, canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options and (ii) $18.00 less the applicable exercise price per share of such options, subject to any applicable withholding or other taxes required by applicable law.
  • [F4]In connection with the Merger, these options were accelerated and canceled without payment.

Issuer

PORTOLA PHARMACEUTICALS INC

CIK 0001269021

Entity typeother

Related Parties

1
  • filerCIK 0001184627

Filing Metadata

Form type
4
Filed
Jul 1, 8:00 PM ET
Accepted
Jul 2, 4:26 PM ET
Size
12.1 KB